Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.

Anticancer research - 1 Dec 2010

Bonanno Laura, Schiavon Marco, Nardo Giorgia, Bertorelle Roberta, Bonaldi Laura, Galligioni Alessandra, Indraccolo Stefano, Pasello Giulia, Rea Federico, Favaretto Adolfo

Abstract excerpt

BACKGROUND/AIM: Gefitinib and erlotinib were shown to be particularly effective in a clinically selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma histology, non-smoking status, Asian origin and female gender have been associated with improved clinical benefit compared to the unselected NSCLC population. The aim of the present study was to investigate the prognostic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Gene Dosage

Share to Genes, erbB-1

Share to Genes, ras

Share to In Situ Hybridization, Fluorescence

Share to Lung Neoplasms

Source

Identifiers

PMID: 21187500

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.PMID 21187500Read ↗

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.Semantic proximity Read ↗

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.Semantic proximity Read ↗

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.Semantic proximity Read ↗

Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.Semantic proximity Read ↗

Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.Semantic proximity Read ↗

Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials.Semantic proximity Read ↗

Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).Semantic proximity Read ↗

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.Semantic proximity Read ↗

Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.